We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New, Portable Lab-on-a-Chip Identifies Concentration of COVID-19 Antibodies in Human Blood In 15 Minutes

By LabMedica International staff writers
Posted on 01 Oct 2020
A new, portable lab-on-a-chip can identify the presence of COVID-19 antibodies in blood with greater speed and efficiency than the current standard “enzyme-linked immunosorbent assay” or ELISA technology.

Researchers from the University of Michigan (Ann Arbor, MI, USA) have developed the device and have shown that it can identify the concentration of COVID-19 antibodies in human blood in 15 minutes. More...
That process normally takes between hours and a few days. The device, which is actually a miniature ELISA, can achieve its faster results with smaller amounts of blood. The work has particular value for the validation of convalescent plasma as a treatment for COVID-19. Microfluidic devices shrink multiple lab functions onto a single chip measured in millimeters or centimeters. In addition to needing smaller sample sizes, they also increase accuracy. This particular system can detect concentration levels of antibodies -something that can vary greatly from plasma donor to donor.

Specifically, the device detects the presence and amount of neutralizing immunoglobulin -antibodies created by the immune system within seven to 10 days of a COVID-19 infection. Only donors with high levels are likely to provide samples that could be effective in treatment, such as convalescent plasma therapy. The treatment involves taking blood from subjects that have previously been diagnosed with COVID-19, and then separating out the plasma - the liquid portion of the blood that contains antibodies. Those antibodies are then given to patients therapeutically in an attempt to boost the immune response. To bolster the data available on convalescent plasma treatments, more donors with high-titer antibody concentrations are needed. The methodology developed by the University of Michigan team provides an efficient and effective way forward.

Screening for proper donors is typically handled by standard ELISA, which requires sample processing and a refrigerator-sized plate-reader for taking measurements. Delays are exacerbated by having to send samples to a lab for analysis. The lab-on-a-chip approach analyzes on site and delivers quantitative evaluations with finger prick’s worth of blood – eight microliters. A traditional ELISA machine requires 100 microliters to do its work. The system is contained in a device the size of a portable 3D printer.

“Convalescent plasma is a treatment that can be very effective – but for it to have the best chance to work, it needs to have rigorous standards, which include assessing the presence of high-titer neutralizing antibodies,” said David Perlin, Ph.D., chief scientific officer and senior vice president of the Hackensack Meridian Center for Discovery and Innovation, and one of the new study’s authors. “This paper shows how the antibody thresholds can mean a better potential COVID-19 treatment – and also better outcomes.”

Related Links:
University of Michigan


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.